Clinical trial
Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study
NCT00363090 is registered in ClinicalTrials.gov with Toronto Sunnybrook Regional Cancer Centre as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study
- Lead sponsor
- Toronto Sunnybrook Regional Cancer Centre
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- September 30, 2006
- Completion date
- Not reported
- Enrollment
- 84 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.